Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report

IF 1.5 Q4 ONCOLOGY Cancer reports Pub Date : 2024-11-15 DOI:10.1002/cnr2.2149

Danilo De Novellis, Pio Zeppa, Elisabetta Maffei, Valentina Giudice, Carmine Selleri, Bianca Serio

{"title":"Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report","authors":"Danilo De Novellis, Pio Zeppa, Elisabetta Maffei, Valentina Giudice, Carmine Selleri, Bianca Serio","doi":"10.1002/cnr2.2149","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and <i>JAK2</i>-mutated myeloproliferative neoplasm with marked splenomegaly.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 11","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564862/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.2149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.

Case Presentation

Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and JAK2-mutated myeloproliferative neoplasm with marked splenomegaly.

Conclusions

We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

达拉单抗治疗髓外肺浆细胞瘤的疗效：病例报告

导言：多发性骨髓瘤（MM）伴有肺髓外疾病非常罕见，通常预后较差：多发性骨髓瘤（MM）伴有肺髓外疾病非常罕见，通常预后较差，目前还没有关于以达拉单抗为基础的治疗方案的数据报道：在这里，一名64岁的肺浆细胞瘤患者接受了达拉单抗治疗，取得了非常好的部分反应，肺部肿块消失，总生存期为16个月。他没有接受自体干细胞移植，因为他有几种合并症，如严重的药物性神经病变和JAK2突变骨髓增生性肿瘤伴明显脾肿大：我们证明了达拉土单抗联合靶向疗法治疗肺癌的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊